Publication: The clinical outcome of intracranial hemangioblastomas treated with linac-based stereotactic radiosurgery and radiotherapy
Issued Date
2014-01-01
Resource Type
ISSN
13499157
04493060
04493060
Other identifier(s)
2-s2.0-84905234369
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Radiation Research. Vol.55, No.4 (2014), 761-768
Suggested Citation
Putipun Puataweepong, Mantana Dhanachai, Ake Hansasuta, Somjai Dangprasert, Chomporn Sitathanee, Parmon Puddhikarant, Chuleeporn Jiarpinitnun, Rawee Ruangkanchanasetr, Patchareporn Dechsupa, Kumutinee Pairat The clinical outcome of intracranial hemangioblastomas treated with linac-based stereotactic radiosurgery and radiotherapy. Journal of Radiation Research. Vol.55, No.4 (2014), 761-768. doi:10.1093/jrr/rrt235 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33924
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The clinical outcome of intracranial hemangioblastomas treated with linac-based stereotactic radiosurgery and radiotherapy
Other Contributor(s)
Abstract
Recent publications have reported stereotactic radiosurgery as an effective and safe treatment for intracranial hemangioblastomas. However, because of the low incidence of these particular tumors, reports on large patient number studies have not yet been available. The objective of this study was to analyze the clinical results of 14 patients with 56 intracranial hemangioblastomas treated with linear accelerator (linac)-based stereotactic radiosurgery (SRS) and radiotherapy (SRT) in the same institute. The median age of patients was 41 years (range, 28-73 years). Nine of the patients (64%) had von Hippel-Lindau disease. A total of 39 lesions (70%) were treated with CyberKnife (CK), and 17 lesions (30%) were treated with X-Knife. The median pretreatment volume was 0.26 cm3 (range, 0.026-20.4 cm3). The median marginal dose was 20 Gy (range, 10-32 Gy) in 1 fraction (range, 1-10 fractions). The median follow-up time was 24 months (range, 11-89 months). At the last follow-up, 47 tumors (84%) were stable, 7 (13%) decreased and 2 (4%) increased. The 1-, 2-and 6-year local control rates were 98%, 88% and 73%, respectively. No radiation complications were observed in this study. There was a trend toward local failure only in cystic tumors, but this trend was not found to be statistically significant. SRS/SRT achieved a high local control rate in intracranial hemangioblastomas without radiation-induced complications. © 2014 The Author.
